ERAS - Erasca Inc
IEX Last Trade
2.88
0.070 2.431%
Share volume: 3,552,250
Last Updated: Fri 30 Aug 2024 09:59:58 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$2.81
0.07
2.49%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
5.09%
1 Month
-9.97%
3 Months
16.53%
6 Months
22.98%
1 Year
10.73%
2 Year
-64.93%
Key data
Stock price
$2.88
DAY RANGE
N/A - N/A
52 WEEK RANGE
$1.51 - $3.45
52 WEEK CHANGE
$0.12
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Jonathan E. Lim
Region: US
Website: erasca.com
Employees: 131
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: erasca.com
Employees: 131
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
our mission at erasca is embedded in our name: to erase cancer in patients by creating a new generation of oncology drugs that we hope will not just treat, but actually cure. energized by recent scientific discoveries and advances in drugging various biological drivers of cancer, we are committed to solving oncology’s hardest problems. we have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals.
Recent news